ArticleRheumatology (Oxford, England)2020
Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis.
Article in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis.Frontiers in medicine · 2022Pooled it
- Immune responses in aging adults.The Journal of clinical investigation · 2026Review
- Associations between plasma metabolism-associated proteins and future development of giant cell arteritis: results from a prospective study.Rheumatology (Oxford, England) · 2025Article
- Predictors of giant cell arteritis in patients with polymyalgia rheumatica in southern Sweden-a retrospective study.Rheumatology advances in practice · 2025Article
- Immune checkpoints in autoimmune vasculitis.Best practice & research. Clinical rheumatology · 2024Review
- Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern Sweden.RMD open · 2024Article
- Apolipoproteins and the risk of giant cell arteritis-a nested case-control study.Arthritis research & therapy · 2024Article
- Giant cell arteritis: reviewing the advancing diagnostics and management.Eye (London, England) · 2023Review
- Analyses of plasma inflammatory proteins reveal biomarkers predictive of subsequent development of giant cell arteritis: a prospective study.Rheumatology (Oxford, England) · 2023Article
- Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis: A Population-Based Study.The Journal of rheumatology · 2023Article
- Immunology of Giant Cell Arteritis.Circulation research · 2023Review
- Common co-morbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank.Rheumatology advances in practice · 2023Article
- Factors predicting death and cancer in patients with giant cell arteritis in Western Norway 1972-2012: a retrospective observational cohort study.Frontiers in medicine · 2023Article
- Article
- Can active sun exposure decrease the risk of giant cell arteritis and polymyalgia rheumatica in women?Rheumatology advances in practice · 2023Article
- An update on polymyalgia rheumatica.Journal of internal medicine · 2022Review
- Global epidemiology of vasculitis.Nature reviews. Rheumatology · 2022Review
- Aging-Related Vascular Inflammation: Giant Cell Arteritis and Neurological Disorders.Frontiers in aging neuroscience · 2022Review
- Pathogenesis of giant cell arteritis with focus on cellular populations.Frontiers in medicine · 2022Review
- Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply.Rheumatology (Oxford, England) · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate metabolic features that may predispose to GCA in a nested case-control study.
methodsIndividuals who developed GCA after inclusion in a population-based health survey (the Malmö Preventive Medicine Project; N = 33 346) were identified and validated through a structured review of medical records. Four controls for every validated case were selected from the database.
resultsA total of 76 cases with a confirmed incident diagnosis of GCA (61% female, 65% biopsy positive, mean age at diagnosis 70 years) were identified. The median time from screening to diagnosis was 20.7 years (range 3.0-32.1). Cases had significantly lower fasting blood glucose (FBG) at baseline screening compared with controls [mean 4.7 vs 5.1 mmol/l (S.d. overall 1.5), odds ratio (OR) 0.35 per mmol/l (95% CI 0.17, 0.71)] and the association remained significant when adjusted for smoking [OR 0.33 per mmol/l (95% CI 0.16, 0.68)]. Current smokers had a reduced risk of GCA [OR 0.35 (95% CI 0.18, 0.70)]. Both cholesterol [mean 5.6 vs 6.0 mmol/l (S.d. overall 1.0)] and triglyceride levels [median 1.0 vs 1.2 mmol/l (S.d. overall 0.8)] were lower among the cases at baseline screening, with significant negative associations with subsequent GCA in crude and smoking-adjusted models [OR 0.62 per mmol/l (95% CI 0.43, 0.90) for cholesterol; 0.46 per mmol/l (95% CI 0.27, 0.81) for triglycerides].
conclusionDevelopment of GCA was associated with lower FBG and lower cholesterol and triglyceride levels at baseline, all adjusted for current smoking, suggesting that metabolic features predispose to GCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.